Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > I think We

<< Previous

Bullboard Posts

Next >>

Comment by davgroon Apr 22, 2022 11:02am

93 Views

Post# 34623704

RE:I think We

Duster340 wrote: just seen some manipulation ate now 70 cents LOL

Yo Dust Pan, do you know anything about trading ?? There was no manipulation here, it wasn't the Illuminati trying to steal shares. Someone decided to unload a large number of shares at the BID which caused the share price to drop quickly. If you watched Level II you could have predicted this happenning. Oh wait, you don't know what level II quotes are. LMAO

<< Previous

Bullboard Posts

Next >>

Catch up with companies that got a Stanley Cup Playoffs boost